Resumen: Durante el 13 al 17 de noviembre de 2020 se llevó a cabo el Congreso Anual de American Heart Association (AHA). Debido a la situación de pandemia que atravesamos, fue realizado de forma virtual en su totalidad, lo que permitió una mayor participación a nivel mundial. Fueron presentadas las Guías de Resucitación Cardiorrespiratoria, así como múltiples estudios interesantes y relevantes para la cardiología, de los cuales destacamos: - Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve: the RIVER trial. - Ferric Carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trail: AFFIRM-AHF trial. - Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease: SCORED trial. - Cardiac Miosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure: the GALACTIC-HF trial. - Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis: RHAPSODY trial. - Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation: the EARLY-AF trial.

Summary: During the 13th-17th november 2020 period, the anual meeting of the American Heart Association was held. Due to the global pandemic situation that we are going through, it was carried out virtually in its entirety, which allowed a greater participation worldwide. The Guidelines for Cardiopulmonary Resucitation were presented as well as multiple interesting and relevant studies for cardiology, from which we highlight: - Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve: the RIVER trial. - Ferric Carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trail: AFFIRM-AHF trial. - Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease: SCORED trial. - Cardiac Miosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure: the GALACTIC-HF trial. - Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis: RHAPSODY trial. - Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation: the EARLY-AF trial.

Resumo: De 13 a 17 de novembro de 2020, foi realizado o congresso anual da American Heart Association. Devido à situação de pandemia global que vivemos, foi feito virtualmente em sua totalidade, o que permitiu uma maior participação em todo o mundo. Foram apresentadas as Diretrizes de Reanimação Cardiorrespiratória, bem como vários estudos interessantes e relevantes para a cardiologia, dos quais destacamos: - Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve: the RIVER trial. - Ferric Carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trail: AFFIRM-AHF trial. - Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease: SCORED trial. - Cardiac Miosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure: the GALACTIC-HF trial. - Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis: RHAPSODY trial. - Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation: the EARLY-AF trial.